In December 2016, after successful results were obtained in children with SMA [33], the FDA approved SPINRAZATM (Nusinersen) as the first and only genetic treatment to date for SMA; this ASO is designed to bind to SMN2 pre-mRNA and promote the inclusion of exon 7. Here, SMN2 is linked to proximal spinal muscular atrophy.